Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 4, 2024. The report details the departure of a senior executive and the terms of the associated separation agreement.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to the specific compensation package for the departing executive:
- Severance Payment: $597,000 (gross), representing 12 months of base salary, payable in bi-weekly installments.
- Annual Incentive Payment: A lump sum based on the 2023 annual incentive plan, adjusted by the corporate multiplier (specific amount not disclosed).
- Healthcare Coverage: Company contributions for up to 12 months of COBRA premiums.
- Legal Fee Reimbursement: Up to $15,000.
- Consulting Fees: $500 per hour for services exceeding 10 hours per month during the consulting period.
Material Changes
The primary material change reported is the departure of Indrani L. Franchini, who served as Executive Vice President, Chief Legal Officer, and Secretary. Her separation became effective on March 1, 2024.
Outlook, Management Commentary, and Risks
Consulting Arrangement: Ms. Franchini will provide consulting and advisory services to the Company for one year, until March 1, 2025. During this period, her unvested equity awards will continue to vest according to the original grant agreement. Stock options will remain exercisable for three months following the consulting period.
Change in Control: In the event of a change in control during the consulting period that triggers acceleration of equity vesting for active employees, Ms. Franchini's awards will be treated identically.
Risks and Contingencies: The filing notes that the description of the separation agreement is qualified by the full text of the agreement filed as Exhibit 10.1. No other operational risks or contingencies are detailed in this specific report.
Key Facts for Investor Verification
- Verify the exact amount of the 2023 annual incentive lump sum payment, as the filing states it is subject to the corporate multiplier but does not disclose the final figure.
- Review the full text of the "Letter Agreement" (Exhibit 10.1) for complete terms regarding the consulting arrangement and equity vesting acceleration.
- Confirm the timeline for the transition of legal and secretarial duties following Ms. Franchini's departure on March 1, 2024.
- Monitor future filings for the appointment of a permanent replacement for the Chief Legal Officer and Secretary roles.